British Land (LSE: BLND) to acquire Life Science REIT in £150m science property deal

The British Land Company plc (LSE: BLND) has announced a recommended cash and share offer for Life Science REIT plc, valuing the specialist property investment trust at approximately £150 million. The acquisition, structured as a court-sanctioned scheme of arrangement, marks a strategic move to deepen British Land’s exposure to the science and technology leasing market across London, Oxford, and Cambridge—collectively known as the UK’s Golden Triangle.

British Land will pay 14.1 pence in cash and issue 0.07 new shares for each Life Science REIT share, implying a total value of 42.8 pence per share based on British Land’s closing price on January 27, 2026. This represents a 21 percent premium to Life Science REIT’s last closing price, but a 26 percent discount to its unaudited EPRA net tangible assets as of December 2025.

Why is British Land targeting life sciences at this point in the cycle despite sector-wide headwinds?

While life sciences real estate has been hit by a macro-driven funding slowdown and tenant hesitation, British Land’s bet appears more focused on medium-term sectoral resilience than short-term sentiment. The company is not acquiring speculative lab development risk; it is buying income-producing science and technology real estate with proven tenant demand and reversionary potential.

British Land has long signaled its ambition to scale in knowledge economy infrastructure—particularly in London’s Knowledge Quarter and innovation clusters such as Oxford and Cambridge. Life Science REIT’s five-asset portfolio adds density in precisely those locations. Roughly 82 percent of the acquired portfolio (by value) is concentrated in Central London, Oxford, and Cambridge, providing campus adjacency and deeper clustering potential with British Land’s existing holdings.

Crucially, less than 6 percent of the acquired portfolio is dedicated wet lab space. This reduces exposure to expensive conversion capex and tenant-specific volatility. British Land is instead inheriting innovation-centric assets with embedded reversion, an 8 percent net reversionary yield, and a weighted average lease term of 4.6 years—at a time when life sciences landlords with greater laboratory concentration are struggling with elevated vacancy.

What execution risks and asset integration challenges could British Land face post-transaction?

The integration thesis hinges on British Land’s ability to fold Life Science REIT’s externally managed platform into its internal asset management operations, stripping out cost duplication while unlocking upside from vacancy absorption and reversion. British Land expects the transaction to be earnings accretive on day one and neutral to EPRA NTA per share, with additional upside expected from leasing newly delivered space—particularly at the Oxford Technology Park, where several buildings remain partially or fully unlet.

However, this synergy capture is not without risk. The underlying cause of Life Science REIT’s managed wind-down—illiquidity, funding constraints, and tepid leasing post-IPO—suggests that asset repositioning may take longer than expected. While British Land boasts a stronger balance sheet and investment-grade credit rating, absorbing development risk, lease-up friction, and maintaining dividend cover during the integration period will test operational discipline.

From a capital structure standpoint, British Land is using its paper (in the form of 0.07 new shares per REIT share) to fund part of the transaction, resulting in dilution of approximately 2.4 percent to existing shareholders. That minimal dilution suggests financial conservatism, but also places pressure on the acquired assets to start contributing meaningfully to free cash flow within a tight timeline.

How does this acquisition reshape British Land’s science and technology leasing strategy?

British Land’s campus strategy is increasingly bifurcated between high-performance office clusters and science and technology innovation hubs. The company has doubled its innovation occupier base since 2022 and launched One Triton Square in October 2025 as a flagship “campus within a campus” concept. The Life Science REIT acquisition enhances this strategy by offering immediate occupancy scale and adjacent landholdings in prime innovation corridors.

British Land executives have made clear that the REIT’s prior “life science only” mandate limited its leasing scope to a narrow universe of biotech and pharma tenants. With the platform integration, British Land will expand the prospective tenant base to include AI research, clean-tech, space-tech, quantum computing, and broader R&D occupiers—a move that mirrors broader global shifts toward multi-disciplinary innovation real estate.

This echoes recent moves in the U.S., where landlords like Alexandria Real Estate Equities have repositioned portions of their wet lab portfolios into dry lab, AI, or climate-tech configurations to capture emerging demand without incurring costly retrofits.

Why did Life Science REIT accept the deal despite the EPRA NTA discount?

From Life Science REIT’s perspective, the deal reflects a pragmatic shift in strategy after persistent macroeconomic headwinds derailed its standalone viability. Since its IPO in 2021, the trust had faced sustained challenges, including inflation-driven yield compression, interest rate shocks, and weakened institutional sentiment in the UK REIT sector. Its shares had traded at a persistent discount to net asset value, and its ability to raise fresh equity to support development capex was significantly impaired.

Following a formal strategic review and a shareholder-approved wind-down process in November 2025, the board was effectively in asset realization mode. In that context, British Land’s bid provided a premium exit price relative to recent indicative offers and allowed shareholders the option of either cashing out or rolling into a more liquid, diversified vehicle with broader sector exposure and dividend visibility.

For shareholders, the access to British Land’s larger balance sheet, superior credit rating, and established dividend track record outweighed the symbolic optics of selling at a discount to net asset value. For British Land, it amounted to opportunistic acquisition of deeply strategic assets at a valuation that avoided overpaying for unproven lab growth.

What investor sentiment signals and shareholder dynamics shaped this outcome?

At the time of the announcement, Life Science REIT had secured support representing over 31 percent of its issued share capital, including irrevocable undertakings from directors, letters of intent from institutional holders, and exposure via derivatives from Saba Capital Management. These commitments significantly de-risk the scheme approval process and suggest that key institutional players saw more upside in British Land’s platform than in continued portfolio divestment.

Life Science REIT’s board was advised by Panmure Liberum, which deemed the terms fair and reasonable after reviewing updated portfolio valuations and evaluating recent bid interest in individual assets. Shareholder sentiment appears to have favored liquidity, optionality, and platform strength over full-cycle value extraction, particularly amid uncertain capital markets and secondary market illiquidity for single-sector REITs.

The transaction is expected to close within three months, pending court approval and shareholder votes. Life Science REIT shareholders will be eligible for British Land’s final dividend for the financial year ending March 2026.

What are the key strategic, financial, and industry implications of British Land’s acquisition of Life Science REIT?

• British Land is acquiring Life Science REIT for £150 million via a recommended cash and share offer, structured as a scheme of arrangement.

• The deal values Life Science REIT at a 21 percent premium to its undisturbed share price but a 26 percent discount to its most recent EPRA NTA.

• The acquisition enhances British Land’s science and technology real estate portfolio, particularly across the Golden Triangle innovation cluster.

• Only a small portion of the acquired portfolio is wet lab space, mitigating retrofit capex risk while providing reversionary leasing upside.

• The deal is expected to be earnings accretive on day one and EPRA NTA per share neutral, supported by administrative cost synergies.

• Life Science REIT’s shareholders gain access to British Land’s larger dividend, stronger liquidity, and a more diversified innovation property platform.

• British Land aims to unlock broader science and tech occupier demand beyond biotech, aligning with shifts in global innovation leasing strategies.

• The deal signals a move away from single-sector REITs toward more resilient, multi-disciplinary innovation campus platforms.

• Institutional investor support—already secured for over 30 percent of REIT shares—suggests high likelihood of shareholder approval.

• The acquisition underscores British Land’s long-term strategic conviction in the science and technology sector, despite current market softness.